Literature DB >> 27892946

First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.

D Ghez1, C Fortpied2, N Mounier3, P Carde1, A Perrot4, H Khaled5, S Amorim6, S Ramadan2, F L Bras7, M Erlanson8, C Herbaux9, J-P Marolleau10, E Nicolas-Virelezier11, O Casasnovas12, A Stamatoullas-Bastard13, C Fermé1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27892946     DOI： 10.1038/bmt.2016.271

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  12 in total

1.  Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

Authors:  Francesco Merli; Stefano Luminari; Paolo G Gobbi; Nicola Cascavilla; Caterina Mammi; Fiorella Ilariucci; Caterina Stelitano; Maurizio Musso; Luca Baldini; Sara Galimberti; Francesco Angrilli; Giuseppe Polimeno; Potito Rosario Scalzulli; Angela Ferrari; Luigi Marcheselli; Massimo Federico
Journal:  J Clin Oncol       Date:  2015-12-28       Impact factor: 44.544

2.  Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group.

Authors:  Diana Wongso; Michael Fuchs; Annette Plütschow; Beate Klimm; Stephanie Sasse; Bernd Hertenstein; Georg Maschmeyer; Tom Vieler; Ulrich Dührsen; Walter Lindemann; Walter Aulitzky; Volker Diehl; Peter Borchmann; Andreas Engert
Journal:  J Clin Oncol       Date:  2013-06-24       Impact factor: 44.544

3.  Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

Authors:  Andreas Engert; Heinz Haverkamp; Carsten Kobe; Jana Markova; Christoph Renner; Antony Ho; Josée Zijlstra; Zdenek Král; Michael Fuchs; Michael Hallek; Lothar Kanz; Hartmut Döhner; Bernd Dörken; Nicole Engel; Max Topp; Susanne Klutmann; Holger Amthauer; Andreas Bockisch; Regine Kluge; Clemens Kratochwil; Otmar Schober; Richard Greil; Reinhard Andreesen; Michael Kneba; Michael Pfreundschuh; Harald Stein; Hans Theodor Eich; Rolf-Peter Müller; Markus Dietlein; Peter Borchmann; Volker Diehl
Journal:  Lancet       Date:  2012-04-04       Impact factor: 79.321

4.  ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

Authors:  Simonetta Viviani; Pier Luigi Zinzani; Alessandro Rambaldi; Ercole Brusamolino; Alessandro Levis; Valeria Bonfante; Umberto Vitolo; Alessandro Pulsoni; Anna Marina Liberati; Giorgina Specchia; Pinuccia Valagussa; Andrea Rossi; Francesco Zaja; Enrico M Pogliani; Patrizia Pregno; Manuel Gotti; Andrea Gallamini; Delia Rota Scalabrini; Gianni Bonadonna; Alessandro M Gianni
Journal:  N Engl J Med       Date:  2011-07-21       Impact factor: 91.245

5.  Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.

Authors:  Peter Borchmann; Heinz Haverkamp; Volker Diehl; Thomas Cerny; Jana Markova; Anthony D Ho; Hans-Theodor Eich; Hans Konrad Mueller-Hermelink; Lothar Kanz; Richard Greil; Andreas Rank; Ursula Paulus; Lenka Smardova; Christoph Huber; Bernd Dörken; Christoph Nerl; Stefan W Krause; Rolf-Peter Mueller; Michael Fuchs; Andreas Engert
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

6.  ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

Authors:  Massimo Federico; Stefano Luminari; Emilio Iannitto; Giuseppe Polimeno; Luigi Marcheselli; Antonella Montanini; Antonio La Sala; Francesco Merli; Caterina Stelitano; Samantha Pozzi; Renato Scalone; Nicola Di Renzo; Pellegrino Musto; Luca Baldini; Giulia Cervetti; Francesco Angrilli; Patrizio Mazza; Maura Brugiatelli; Paolo G Gobbi
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

7.  Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.

Authors:  Franck Morschhauser; Pauline Brice; Christophe Fermé; Marine Diviné; Gilles Salles; Reda Bouabdallah; Catherine Sebban; Laurent Voillat; Olivier Casasnovas; Aspasia Stamatoullas; Krimo Bouabdallah; Marc André; Jean-Philippe Jais; Dominique Cazals-Hatem; Christian Gisselbrecht
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

8.  Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.

Authors:  Patrice Carde; Matthias Karrasch; Catherine Fortpied; Pauline Brice; Hussein Khaled; Olivier Casasnovas; Denis Caillot; Isabelle Gaillard; Serge Bologna; Christophe Ferme; Pieternella Johanna Lugtenburg; Frank Morschhauser; Igor Aurer; Bertrand Coiffier; Ralph Meyer; Matthew Seftel; Max Wolf; Bengt Glimelius; Anna Sureda; Nicolas Mounier
Journal:  J Clin Oncol       Date:  2016-04-25       Impact factor: 44.544

9.  ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.

Authors:  N Mounier; P Brice; S Bologna; J Briere; I Gaillard; M Heczko; J Gabarre; O Casasnovas; J Jaubert; P Colin; A Delmer; A Devidas; E Bachy; E Nicolas-Virelizier; A Aoudjhane; C Humbrecht; M Andre; P Carde
Journal:  Ann Oncol       Date:  2014-05-14       Impact factor: 32.976

Review 10.  Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.

Authors:  Nicole Skoetz; Sven Trelle; Michaela Rancea; Heinz Haverkamp; Volker Diehl; Andreas Engert; Peter Borchmann
Journal:  Lancet Oncol       Date:  2013-08-13       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.